VENTASWITCH, Examination of Ventavis® (Iloprost) Inhalation Behavior Using the I-Neb® AAD® System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

Trial Profile

VENTASWITCH, Examination of Ventavis® (Iloprost) Inhalation Behavior Using the I-Neb® AAD® System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Iloprost (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms VENTASWITCH
  • Sponsors Bayer
  • Most Recent Events

    • 14 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 25 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.
    • 25 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top